von Pawel, J., Bordoni, R., Satouchi, M., Fehrenbacher, L., Cobo, M., Han, J., Hida, T., Moro-Sibilot, D., Conkling, P., Gandara, D., Rittmeyer, A., Gandhi, M., Yu, W., Matheny, C., Patel, H., Sandler, A., Ballinger, M., Kowanetz, M., & Park, K. (2019). long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. European journal of cancer, 107, 124–132. http://access.bl.uk/ark:/81055/vdc_100076770456.0x000024